502 related articles for article (PubMed ID: 21506645)
21. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice.
Dendouga N; Fochesato M; Lockman L; Mossman S; Giannini SL
Vaccine; 2012 Apr; 30(20):3126-35. PubMed ID: 22326899
[TBL] [Abstract][Full Text] [Related]
22. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.
Vandepapelière P; Rehermann B; Koutsoukos M; Moris P; Garçon N; Wettendorff M; Leroux-Roels G
Vaccine; 2005 Apr; 23(20):2591-601. PubMed ID: 15780441
[TBL] [Abstract][Full Text] [Related]
23. Novel adjuvant systems.
McCluskie MJ; Weeratna RD
Curr Drug Targets Infect Disord; 2001 Nov; 1(3):263-71. PubMed ID: 12455400
[TBL] [Abstract][Full Text] [Related]
24. Toll-like receptor 4 signaling in hematopoietic-lineage cells contributes to the enhanced activity of the human vaccine adjuvant AS01.
Van Maele L; Fougeron D; Cayet D; Chalon A; Piccioli D; Collignon C; Sirard JC; Didierlaurent AM
Eur J Immunol; 2019 Dec; 49(12):2134-2145. PubMed ID: 31489613
[TBL] [Abstract][Full Text] [Related]
25. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach.
Garçon N; Morel S; Didierlaurent A; Descamps D; Wettendorff M; Van Mechelen M
BioDrugs; 2011 Aug; 25(4):217-26. PubMed ID: 21815697
[TBL] [Abstract][Full Text] [Related]
26. Development of a leishmaniasis vaccine: the importance of MPL.
Reed SG; Coler RN; Campos-Neto A
Expert Rev Vaccines; 2003 Apr; 2(2):239-52. PubMed ID: 12899575
[TBL] [Abstract][Full Text] [Related]
27. [The importance of the second generation adjuvanted systems in "new" vaccines].
Beran J
Klin Mikrobiol Infekc Lek; 2008 Feb; 14(1):5-12. PubMed ID: 18327735
[TBL] [Abstract][Full Text] [Related]
28. CCR2- and Flt3-Dependent Inflammatory Conventional Type 2 Dendritic Cells Are Necessary for the Induction of Adaptive Immunity by the Human Vaccine Adjuvant System AS01.
Bosteels C; Fierens K; De Prijck S; Van Moorleghem J; Vanheerswynghels M; De Wolf C; Chalon A; Collignon C; Hammad H; Didierlaurent AM; Lambrecht BN
Front Immunol; 2020; 11():606805. PubMed ID: 33519816
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.
Laupèze B; Hervé C; Di Pasquale A; Tavares Da Silva F
Vaccine; 2019 Sep; 37(38):5670-5680. PubMed ID: 31420171
[TBL] [Abstract][Full Text] [Related]
30. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
[TBL] [Abstract][Full Text] [Related]
31. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
Coccia M; Collignon C; Hervé C; Chalon A; Welsby I; Detienne S; van Helden MJ; Dutta S; Genito CJ; Waters NC; Deun KV; Smilde AK; Berg RAVD; Franco D; Bourguignon P; Morel S; Garçon N; Lambrecht BN; Goriely S; Most RV; Didierlaurent AM
NPJ Vaccines; 2017; 2():25. PubMed ID: 29263880
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials.
Tielemans CL; Vlasak J; Kosa D; Billiouw JM; Verpooten GA; Mezei I; Ryba M; Peeters PC; Mat O; Jadoul MY; Polakovic V; Dhaene M; Treille S; Kuriyakose SO; Leyssen M; Houard SA; Surquin M
Vaccine; 2011 Feb; 29(6):1159-66. PubMed ID: 21167859
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults.
van den Berg RA; De Mot L; Leroux-Roels G; Bechtold V; Clement F; Coccia M; Jongert E; Evans TG; Gillard P; van der Most RG
Front Immunol; 2018; 9():564. PubMed ID: 29632533
[TBL] [Abstract][Full Text] [Related]
34. The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes.
Neeland MR; Shi W; Collignon C; Taubenheim N; Meeusen EN; Didierlaurent AM; de Veer MJ
J Immunol; 2016 Oct; 197(7):2704-14. PubMed ID: 27549170
[TBL] [Abstract][Full Text] [Related]
35. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
Drane D; Gittleson C; Boyle J; Maraskovsky E
Expert Rev Vaccines; 2007 Oct; 6(5):761-72. PubMed ID: 17931156
[TBL] [Abstract][Full Text] [Related]
36. [Adjuvants as factors improving efficiency of vaccination].
Chodaczek G
Postepy Hig Med Dosw (Online); 2004 Mar; 58():47-59. PubMed ID: 15069382
[TBL] [Abstract][Full Text] [Related]
37. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy.
Baldrick P; Richardson D; Woroniecki SR; Lees B
J Appl Toxicol; 2007; 27(4):399-409. PubMed ID: 17299813
[TBL] [Abstract][Full Text] [Related]
38. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
Schwarz TF
Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
[TBL] [Abstract][Full Text] [Related]
39. Unmet needs in modern vaccinology: adjuvants to improve the immune response.
Leroux-Roels G
Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254
[TBL] [Abstract][Full Text] [Related]
40. Comparison of liposome-polycation-DNA(LPD) and monophosphoryl lipid A(MPL) adjuvant formulations in BALB/c mice models.
Zhang XP; Cui WH
Immunol Invest; 2012; 41(4):356-66. PubMed ID: 21864115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
